PHARMACEUTICAL COMPOSITION COMPRISING P-GLYCOPROTEIN INHIBITOR AND P-GLYCOPROTEIN SUBSTRATE DRUG

摘要

The present invention relates to a pharmaceutical composition including a p-glycoprotein inhibitor and a p-glycoprotein substrate drug. The pharmaceutical composition of the present invention can reduce side effects of a drug caused by activity of p-glycoprotein and furthermore can provide the same pharmaceutical effect even when a smaller amount of the drug is used. Particularly, when dabigatran etexilate, which is the p-glycoprotein substrate drug, and a tetrazole deravative, which is the p-glycoprotein inhibitor, are used at the same time, bioavailability of dabigatran etexilate can be significantly increased. Consequently, a remaining amount of dabigatran etexilate in a gastrointestinal tract can be significantly reduced as the drug has the same level of bioavailability even when a user amount of the drug is reduced. In addition, an exposure amount of the drug in the gastrointestinal tract is reduced. Therefore, the pharmaceutical composition of the present invention can reduce the risk of bleeding, a fatal drawback for patients who takes existing dabigatran etexilate.